Evidence map›Paper›PMID 35788749›Full record

Trial reportPLoS neglected tropical diseases2022

Cervical lesion proportion measure using a digital gridded imaging technique to assess cervical pathology in women with genital schistosomiasis.

Louise Thomsen Schmidt Arenholt, Katrina Kaestel Aaroe, Kanutte Norderud, Mads Lumholdt, Bodo Sahondra Randrianasolo, Charles Emile Ramarokoto, Oliva Rabozakandraina, Dorthe Broennum, Hermann Feldmeier, Peter Derek Christian Leutscher

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04115072 (Treatment of Female Genital Schistosomiasis), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04115072 phase2 / phase3completednot on this map

Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study

TypeinterventionalSponsorRegionshospital NordjyllandRan2019 to 2020Enrolled116ConditionsSchistosomiasisArmsPraziquantel 600Mg Oral Tablet x 5, Praziquantel 600Mg Oral Tablet x 1
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Louise Thomsen Schmidt ArenholtCentre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark.
Katrina Kaestel AaroeCentre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark.
Kanutte NorderudCentre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark.
Mads LumholdtCentre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark.
Bodo Sahondra RandrianasoloAssociation K'OLO VANONA, Antananarivo, Madagascar.
Charles Emile RamarokotoAssociation K'OLO VANONA, Antananarivo, Madagascar.
Oliva RabozakandrainaAssociation K'OLO VANONA, Antananarivo, Madagascar.
Dorthe BroennumCentre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark.
Hermann FeldmeierInstitute of Microbiology and Infectious Diseases Immunology, Campus Benjamin Franklin, Charité-University Medicine Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Peter Derek Christian LeutscherCentre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark.ORCID 0000-0002-6742-8939
North Denmark Region · DKAssociation Vahatra · MGHumboldt-Universität zu Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Female genital schistosomiasis (FGS) is characterized by a pattern of lesions which manifest at the cervix and the vagina, such as homogeneous and grainy sandy patches, rubbery papules in addition to neovascularization. A tool for quantification of the lesions is needed to improve FGS research and control programs. Hitherto, no tools are available to quantify clinical pathology at the cervix in a standardized and reproducible manner. This study aimed to develop and validate a cervical lesion proportion (CLP) measure for quantification of cervical pathology in FGS. A digital imaging technique was applied in which a grid containing 424 identical squares was positioned on high resolution digital images from the cervix of 70 women with FGS. CLP was measured for each image by observers counting the total number of squares containing at least one type of FGS associated lesion. For assessment of inter- and intra-observer reliability, three different observers measured CLP independently. In addition, a rubbery papule count (RPC) was determined in a similar manner. The intraclass correlation coefficient was 0.94 (excellent) for the CLP inter-rater reliability and 0.90 (good) for intra-rater reliability and the coefficients for the RPC were 0.88 and 0.80 (good), respectively. The CLP facilitated a reliable and reproducible quantification of FGS associated lesions of the cervix. In the future, grading of cervical pathology by CLP may provide insight into the natural course of schistosome egg-induced pathology of the cervix and may have a role in assessing praziquantel treatment efficacy against FGS. Trial Registration: ClinicalTrials.gov, trial number NCT04115072; trial URL https://clinicaltrials.gov/ct2/show/NCT04115072?term=Female+genital+schistosomiasis+AND+Madagascar&draw=2&rank=1.

Indexed as

Schistosoma haematobiumSchistosomiasis haematobiaAnimalsCervix UteriFemaleHumansReproducibility of ResultsVagina

Identifiers

PMID35788749
PMCPMC9286223
OpenAlexW4283836411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.